Neurological and Psychiatric Conditions

MDD incidence rates ranged from 12.6 to 72.0 per 1000 person-years, varying substantially across databases. Photobiomodulation research spans neurological, psychiatric, and systemic conditions. The intention-to-treat analysis found no statistically significant association between BP-CCB initiation and any of the four neuropsychiatric outcomes. Synaptic dysfunction is a core pathological feature of bipolar disorder, schizophrenia, and depression, making CaV1.2 a plausible therapeutic target. Schizophrenia is usually first diagnosed between the late teens and early 30s, making the older CCB-initiator population atypical for that outcome. The study's four primary incident outcomes were schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Photobiomodulation is being investigated for its potential applications in Alzheimer's disease, ADHD, PTSD, Parkinson's disease, autism, depression, and anxiety disorders.